{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:23:32Z","timestamp":1790256212450,"version":"4.1.0"},"reference-count":126,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007185","name":"University of California Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007185","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ymthe.2025.12.022","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:29:48Z","timestamp":1765474188000},"page":"1326-1339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Redefining multiple sclerosis with CAR-T cell therapy"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9858-300X","authenticated-orcid":false,"given":"Yan-Ruide","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.12.022_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2025.12.022_bib2","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s41577-022-00718-z","article-title":"The immunology of multiple sclerosis","volume":"22","author":"Attfield","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri3871","article-title":"Immunopathology of multiple sclerosis","volume":"15","author":"Dendrou","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib4","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.12.022_bib5","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.medj.2021.01.006","article-title":"Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosis","volume":"2","author":"Kaufmann","year":"2021","journal-title":"Med"},{"key":"10.1016\/j.ymthe.2025.12.022_bib6","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/brain\/awm038","article-title":"Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology","volume":"130","author":"Magliozzi","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.ymthe.2025.12.022_bib7","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1001\/jamaneurol.2023.1184","article-title":"Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis","volume":"80","author":"Kalincik","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib8","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/archneur.62.2.258","article-title":"Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis","volume":"62","author":"Monson","year":"2005","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib9","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.ymthe.2025.12.022_bib10","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1182\/blood-2024-205103","article-title":"CD19-Directed CAR T Cell Therapy in 4 Patients with Refractory Multiple Sclerosis","volume":"144","author":"Richter","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.12.022_bib11","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.tips.2024.07.005","article-title":"Frontiers in CAR-T cell therapy for autoimmune diseases","volume":"45","author":"Li","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ymthe.2025.12.022_bib12","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.12.022_bib13","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.12.022_bib14","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.12.022_bib15","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ymthe.2025.12.022_bib16","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","article-title":"Anti-CD19 CAR T cells for refractory myasthenia gravis","volume":"22","author":"Haghikia","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib17","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ymthe.2025.12.022_bib18","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/ard-2023-225174","article-title":"Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis","volume":"83","author":"Merkt","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ymthe.2025.12.022_bib19","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.12.022_bib20","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1600-065X.2010.00945.x","article-title":"B-cell targeted therapies in human autoimmune diseases: an updated perspective","volume":"237","author":"Townsend","year":"2010","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ymthe.2025.12.022_bib21","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.12.022_bib22","article-title":"B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy?","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib23","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1128\/IAI.03099-14","article-title":"Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia","volume":"83","author":"Elsegeiny","year":"2015","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ymthe.2025.12.022_bib24","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ymthe.2025.12.022_bib25","doi-asserted-by":"crossref","first-page":"76","DOI":"10.20411\/pai.v6i1.435","article-title":"COVID-19 Outcomes in Patients Undergoing B Cell Depletion Therapy and Those with Humoral Immunodeficiency States: A Scoping Review","volume":"6","author":"Jones","year":"2021","journal-title":"Pathog. Immun."},{"key":"10.1016\/j.ymthe.2025.12.022_bib26","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3389\/fimmu.2018.00622","article-title":"B Cell Modulation Strategies in Autoimmune Diseases: New Concepts","volume":"9","author":"Musette","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jneuroim.2006.06.029","article-title":"Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients","volume":"180","author":"Cross","year":"2006","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1212\/WNL.0000000000001586","article-title":"Meningeal inflammation in multiple sclerosis: The key to the origin of cortical lesions?","volume":"85","author":"Mainero","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.12.022_bib29","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/brain\/awr182","article-title":"Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis","volume":"134","author":"Howell","year":"2011","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2025.12.022_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103264","article-title":"Acting centrally or peripherally: A renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis","volume":"56","author":"Correale","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.ymthe.2025.12.022_bib31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.12.022_bib32","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of Monoclonal Antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT. Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib33","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1038\/s41467-024-46321-9","article-title":"Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria","volume":"15","author":"Foss","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.12.022_bib34","doi-asserted-by":"crossref","first-page":"H1","DOI":"10.1530\/VB-19-0033","article-title":"Immune cell trafficking across the blood-brain barrier in the absence and presence of neuroinflammation","volume":"2","author":"Marchetti","year":"2020","journal-title":"Vasc. Biol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib35","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1600-065X.2012.01127.x","article-title":"Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models","volume":"248","author":"Takeshita","year":"2012","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ymthe.2025.12.022_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.805657","article-title":"How Does the Immune System Enter the Brain?","volume":"13","author":"Mapunda","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib37","article-title":"Interaction between Th17 and central nervous system in multiple sclerosis","volume":"43","author":"Lai","year":"2025","journal-title":"Brain Behav. Immun. Health"},{"key":"10.1016\/j.ymthe.2025.12.022_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1595276","article-title":"Multiple sclerosis: etiology in the context of neurovascular unit and immune system involvement and advancements with in vitro blood-brain barrier models","volume":"16","author":"El-Taibany","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib39","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1007\/s10787-025-01955-z","article-title":"Beyond the blood\u2013brain barrier: unraveling T cell subsets in CNS immunity and disease","volume":"33","author":"Shokr","year":"2025","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.ymthe.2025.12.022_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.607766","article-title":"Ectopic Lymphoid Follicles in Multiple Sclerosis: Centers for Disease Control?","volume":"11","author":"Negron","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib41","first-page":"14","article-title":"Multiple sclerosis: 2024 update","volume":"6","author":"Klotz","year":"2025","journal-title":"Free Neuropathol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib42","article-title":"Harnessing the chemokine system to home CAR-T cells into solid tumors","volume":"3","author":"Foeng","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2025.12.022_bib43","doi-asserted-by":"crossref","first-page":"9914","DOI":"10.1038\/s41467-025-64861-6","article-title":"Engineered CXCR3-A expression enhances B7-H3-targeting CAR T cell migration and efficacy against diffuse intrinsic pontine glioma","volume":"16","author":"Song","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.12.022_bib44","doi-asserted-by":"crossref","first-page":"7358","DOI":"10.21037\/tcr-2025-1920","article-title":"CXCR3 enhanced murine chimeric antigen receptor T cells in the treatment of solid tumors","volume":"14","author":"Zhang","year":"2025","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.12.022_bib45","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1038\/s41467-022-29647-0","article-title":"Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.12.022_bib46","article-title":"CAR T cell therapy for central nervous system solid tumors: current progress and future directions","volume":"16","author":"Kaminskiy","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110528","article-title":"T cell trafficking in human chronic inflammatory diseases","volume":"27","author":"Giovenzana","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.ymthe.2025.12.022_bib48","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1007\/s40120-025-00831-w","article-title":"Selective S1P Receptor Modulation in Multiple Sclerosis Alters CXCL13:CXCR5-Associated Immune Activities Without Impacting Anti-SARS-CoV-2 Immunity","volume":"14","author":"Harrer","year":"2025","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.ymthe.2025.12.022_bib49","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/s41423-018-0198-5","article-title":"CD70 defines a subset of proinflammatory and CNS-pathogenic T(H)1\/T(H)17 lymphocytes and is overexpressed in multiple sclerosis","volume":"16","author":"Dhaeze","year":"2019","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib50","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood.2020008221","article-title":"CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.12.022_bib51","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.12.022_bib52","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-023-00822-w","article-title":"Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ymthe.2025.12.022_bib53","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial","volume":"39","author":"Pan","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib54","article-title":"Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells","volume":"6","author":"Li","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2025.12.022_bib55","article-title":"CD70 CAR T cells in AML: Form follows function","volume":"3","author":"Mirazee","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2025.12.022_bib56","article-title":"CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells","volume":"6","author":"Wang","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2025.12.022_bib57","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.12.022_bib58","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI insight"},{"key":"10.1016\/j.ymthe.2025.12.022_bib59","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.omto.2019.08.002","article-title":"Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin\u2019s Lymphoma","volume":"15","author":"Ying","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2025.12.022_bib60","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41408-021-00508-1","article-title":"AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia","volume":"11","author":"Nawaz","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ymthe.2025.12.022_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006292","article-title":"Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering","volume":"11","author":"Michels","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.12.022_bib62","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.12.022_bib63","article-title":"From bench to body: In vivo CAR engineering in the clinic","volume":"6","author":"Li","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2025.12.022_bib64","article-title":"Clinical technology advances driving in vivo CAR therapy","author":"Li","year":"2025","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib65","doi-asserted-by":"crossref","first-page":"9287","DOI":"10.1038\/s41467-024-53657-9","article-title":"Protective effect of TCR-mediated MAIT cell activation during experimental autoimmune encephalomyelitis","volume":"15","author":"Walkenhorst","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.12.022_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00014","article-title":"The Emerging Roles of Gamma\u2013Delta T Cells in Tissue Inflammation in Experimental Autoimmune Encephalomyelitis","volume":"7","author":"Malik","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib67","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.ymthe.2025.12.022_bib68","first-page":"3791","article-title":"Myelin oligodendrocyte glycoprotein (MOG35-55) induced experimental autoimmune encephalomyelitis (EAE) in C57BL\/6 mice","volume":"10","author":"Bittner","year":"2014","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.ymthe.2025.12.022_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104222","article-title":"Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression","volume":"358","author":"De Paula Pohl","year":"2020","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib70","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/brain\/awab093","article-title":"Formation and immunomodulatory function of meningeal B cell aggregates in progressive CNS autoimmunity","volume":"144","author":"Mitsdoerffer","year":"2021","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2025.12.022_bib71","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abo0777","article-title":"Antigen-specific depletion of CD4(+) T cells by CAR T cells reveals distinct roles of higher- and lower-affinity TCRs during autoimmunity","volume":"7","author":"Yi","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib72","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200080","article-title":"CAR-T Cell-Mediated B-Cell Depletion in Central Nervous System Autoimmunity","volume":"10","author":"Gupta","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.ymthe.2025.12.022_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1235222","article-title":"CAR-T cells and CAR-Tregs targeting conventional type-1 dendritic cell suppress experimental autoimmune encephalomyelitis","volume":"14","author":"Moorman","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e19763","article-title":"Engineering chimeric autoantibody receptor T cells for targeted B cell depletion in multiple sclerosis model: An in-vitro study","volume":"9","author":"Sahlolbei","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.ymthe.2025.12.022_bib75","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.12.022_bib76","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.ymthe.2025.12.022_bib77","article-title":"Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy","volume":"10","author":"Chen","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.ymthe.2025.12.022_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100804","article-title":"Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells","volume":"6","author":"Li","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.ymthe.2025.12.022_bib79","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.clim.2012.05.010","article-title":"Immune modulating peptides for the treatment and suppression of multiple sclerosis","volume":"144","author":"Badawi","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib80","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1038\/s41591-025-03937-8","article-title":"Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial","volume":"31","author":"Feng","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.12.022_bib81","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2025.12.022_bib82","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy-assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib83","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib84","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18102048","article-title":"Deciphering the Role of B Cells in Multiple Sclerosis-Towards Specific Targeting of Pathogenic Function","volume":"18","author":"Lehmann-Horn","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2025.12.022_bib85","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00401-023-02552-6","article-title":"IL-10-providing B cells govern pro-inflammatory activity of macrophages and microglia in CNS autoimmunity","volume":"145","author":"Geladaris","year":"2023","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib86","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3389\/fimmu.2015.00636","article-title":"B Cells in the Multiple Sclerosis Central Nervous System: Trafficking and Contribution to CNS-Compartmentalized Inflammation","volume":"6","author":"Michel","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib87","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12974-019-1517-1","article-title":"Impact of B cells to the pathophysiology of multiple sclerosis","volume":"16","author":"Arneth","year":"2019","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.ymthe.2025.12.022_bib88","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1038\/s41467-024-46448-9","article-title":"Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus","volume":"15","author":"Doglio","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.12.022_bib89","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric antigen receptor T cell therapy for autoimmune disease","volume":"24","author":"Chung","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.611795","article-title":"Immunosuppressive Mechanisms of Regulatory B Cells","volume":"12","author":"Catal\u00e1n","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib91","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.12.022_bib92","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.12.022_bib93","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade letter","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.12.022_bib94","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.12.022_bib95","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3324\/haematol.2008.001677","article-title":"Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy","volume":"94","author":"Griffioen","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.ymthe.2025.12.022_bib96","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.12.022_bib97","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","article-title":"Chimeric antigen receptor T-cell therapies for lymphoma","volume":"15","author":"Brudno","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib98","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41577-024-01093-7","article-title":"From TCR fundamental research to innovative chimeric antigen receptor design","volume":"25","author":"Minguet","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib99","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib100","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123672","article-title":"Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in regulatory T cells","volume":"4","author":"Dawson","year":"2019","journal-title":"JCI insight"},{"key":"10.1016\/j.ymthe.2025.12.022_bib101","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3389\/fimmu.2017.01125","article-title":"Chimeric Antigen Receptor-Redirected Regulatory T Cells Suppress Experimental Allergic Airway Inflammation, a Model of Asthma","volume":"8","author":"Skuljec","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.ymthe.2025.12.022_bib103","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41587-024-02226-y","article-title":"Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method","volume":"43","author":"Li","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib104","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/s41467-025-56270-6","article-title":"Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies","volume":"16","author":"Li","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.12.022_bib105","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13287-022-02787-2","article-title":"Development of off - the - shelf hematopoietic stem cell - engineered invariant natural killer T cells for COVID - 19 therapeutic intervention","volume":"13","author":"Li","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.ymthe.2025.12.022_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116439","article-title":"Molecular mechanism of co-stimulatory domains in promoting CAR-T cell anti-tumor efficacy","volume":"227","author":"Zhao","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115973","article-title":"CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients","volume":"44","author":"Cook","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2025.12.022_bib108","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.immuni.2011.12.007","article-title":"Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development","volume":"36","author":"van der Windt","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.12.022_bib109","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.immuni.2014.06.005","article-title":"Memory CD8(+) T cells use cell-intrinsic lipolysis to support the metabolic programming necessary for development","volume":"41","author":"O\u2019Sullivan","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.12.022_bib110","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148546","article-title":"Targeting memory T cell metabolism to improve immunity","volume":"132","author":"Corrado","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.12.022_bib111","doi-asserted-by":"crossref","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","article-title":"Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells","volume":"113","author":"Hurton","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.12.022_bib112","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.molmed.2025.05.014","article-title":"IL-15 in CAR engineering: striking an efficacy-safety balance","volume":"31","author":"Li","year":"2025","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ymthe.2025.12.022_bib113","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","article-title":"CAR T Cells Releasing IL-18 Convert to T-Bet(high) FoxO1(low) Effectors that Exhibit Augmented Activity against Advanced Solid Tumors","volume":"21","author":"Chmielewski","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2025.12.022_bib114","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.trecan.2025.06.008","article-title":"IL-18 revives dysfunctional CAR-T cells","volume":"11","author":"Li","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ymthe.2025.12.022_bib115","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006522","article-title":"Metabolic reprogramming via an engineered PGC-1\u03b1 improves human chimeric antigen receptor T-cell therapy against solid tumors","volume":"11","author":"Lontos","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.12.022_bib116","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1016\/j.ymthe.2024.11.035","article-title":"Managing allorejection in off-the-shelf CAR-engineered cell therapies","volume":"33","author":"Li","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.12.022_bib117","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"Off-the-shelf allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.12.022_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.stemcr.2025.102515","article-title":"Engineering the next generation of allogeneic CAR cells: iPSCs as a scalable and editable platform","volume":"20","author":"Fang","year":"2025","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.ymthe.2025.12.022_bib119","article-title":"Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy","volume":"2","author":"Li","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2025.12.022_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100677","article-title":"Emerging trends in clinical allogeneic CAR cell therapy","volume":"6","author":"Li","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.ymthe.2025.12.022_bib121","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41577-025-01174-1","article-title":"In vivo CAR engineering for immunotherapy","volume":"25","author":"Li","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.12.022_bib122","first-page":"241","article-title":"Autologous, allogeneic, in vivo CAR for autoimmune diseases","volume":"S0165\u20136147","author":"Li","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ymthe.2025.12.022_bib123","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","article-title":"In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma","volume":"406","author":"Xu","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.12.022_bib124","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.12.022_bib125","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.trecan.2025.03.001","article-title":"The clinical landscape of CAR-engineered unconventional T cells","volume":"11","author":"Li","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ymthe.2025.12.022_bib126","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ccell.2024.11.010","article-title":"Breaking the mold: Unconventional T cells in cancer therapy","volume":"43","author":"Li","year":"2025","journal-title":"Cancer Cell"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625010457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625010457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T14:39:03Z","timestamp":1786027143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625010457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":126,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1525001625010457"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.12.022","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Redefining multiple sclerosis with CAR-T cell therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.12.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}